Difference between revisions of "Template:Current week ecosystem agenda"

Revision as of 12:04, 29 April 2024

Oroboros declares solidarity against the Russian aggression-war in Ukraine and against all aggression-wars worldwide. - »More details

-» A future for Ukraine is the future of its science

2024 Week 18

Apr-29 Mo

How can I update DatLab 8 to the latest version?

If your computer with DatLab 8 is connected to the internet, go to “Check for updates” in the Help menu of DatLab 8, and follow the simple installation instructions.
- »Updating - DatLab«, »DatLab 8«
- communicated by »Leo Elettra« and »Baglivo Eleonora«

Apr-30 Tu

May-01 We

May-02 Th

"In respirometric studies on blood cells, the purity of cell preparation should always be emphasized and documented."

- »MiPNet21.17 BloodCellsIsolation«
- communicated by »Timon-Gomez Alba« and »Baglivo Eleonora«

May-03 Fr

Next Week

2024 Week 19

May-06 Mo

What is the effective concentration of digitonin for complete plasma membrane permeabilization?

It needs to be determined for each cell type and digitonin batch. The SUIT protocol SUIT-010 was designed to evaluate the optimum digitonin concentration to permeabilize the plasma membrane.
- »Digitonin«, »SUIT-010«
- communicated by »Schmitt Sabine« and »Timon-Gomez Alba«

May-07 Tu

May-08 We

May-09 Th

May-10 Fr

@@ Line 1: / Line 1: @@
 {{Template:Science for Ukraine}}
-Week 34
+Week 18
-*'''Aug- 21 Mo'''
+* '''Apr-29 Mo'''
+:{|
+| width="110" align="center" | [[Image:O2k-Support.jpg|60px|link=http://wiki.oroboros.at/index.php/O2k-Open_Support |O2k-Open Support]][[File:Blue-info.png|25px|Info: improve]]
+|'''How can I update DatLab 8 to the latest version?'''<br>
+If your computer with DatLab 8 is connected to the internet, go to “Check for updates” in the Help menu of DatLab 8, and follow the simple installation instructions. <br>
+- »'''[[Updating - DatLab]]'''«, »'''[https://www.oroboros.at/index.php/product/datlab/ DatLab 8]'''«<br>
+- communicated by »[[Leo Elettra]]« and »[[Baglivo Eleonora]]«
+|}
+----
+* '''Apr-30 Tu'''
+----
+* '''May-01 We'''
+----
+* '''May-02 Th'''
+:{|
+| width="110" align="center" | [[Image:O2k-Support.jpg|60px|link=http://wiki.oroboros.at/index.php/O2k-Open_Support |O2k-Open Support]][[File:Blue-info.png|25px|Info: improve]]
+|''' "In respirometric studies on blood cells, the purity of cell preparation should always be emphasized and documented." '''<br>
+- »'''[[MiPNet21.17 BloodCellsIsolation]]'''«<br>
+- communicated by »[[Timon-Gomez Alba]]« and »[[Baglivo Eleonora]]«
+|}
 ----
-*'''Aug- 22 Tu'''
+* '''May-03 Fr'''
+'''<big>Next Week</big>'''
+Week 19
+* '''May-06 Mo'''
 :{|
 | width="110" align="center" | [[File:MitoPedia.jpg|left|80px|MitoPedia|link=MitoPedia]]
-|''' Are pyruvate, glutamate, and malate substrates of Complex I?'''<br>
+|''' What is the effective concentration of digitonin for complete plasma membrane permeabilization?'''<br>
-No, NADH is a Complex I substrate. However, pyruvate, glutamate and malate are used in high-resolution respirometry as substrates for mitochondrial dehydrogenases to generate NADH in the mitochondrial matrix because NADH cannot cross the mitochondrial inner membrane. <br>
+It needs to be determined for each cell type and digitonin batch. The SUIT protocol SUIT-010 was designed to evaluate the optimum digitonin concentration to permeabilize the plasma membrane. <br>
-- »'''[[NADH electron transfer-pathway state]]'''« and »'''[[Complex I]]'''« <br>
+- »'''[[Digitonin]]'''«, »'''[[SUIT-010]]'''« <br>
-- communicated by »[[Cardoso Luiza]]« and »[[Grings Mateus]]«
+- communicated by »[[Schmitt Sabine]]« and »[[Timon-Gomez Alba]]«
 |}
 ----
-*'''Aug- 23 We'''
+* '''May-07 Tu'''
 ----
-*'''Aug- 24 Th'''
+* '''May-08 We'''
 ----
-:{|
+* '''May-09 Th'''
-| width="100" align="center" |[[File:FAT4BRAIN logo.png|80px|link=https://wiki.oroboros.at/index.php/FAT4BRAIN |FAT4BRAIN]]
-|'''"Understanding acylcarnitine metabolic and signaling pathways provides a better rationale for selecting targets for therapeutic interventions."''' <br>
-* Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, Smesny S, Sen ZD, Guo AC, Oler E, Tian S, Zheng J, Wishart DS, Liepinsh E, Schioth HB. (2022) Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials.  [[Dambrova 2022 Pharmacol Rev|»Bioblast link«]]
-:from the O2k-Network »[[LV Riga Liepins E]]«
-|}
-*'''Aug- 25 Fr'''
 ----
+* '''May-10 Fr'''